

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

<p>BSE Limited 1st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u></p> <p>Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u></p> <p>Kind Attn.: Famroze Pochara Asst. Vice President</p>
<p>Date: May 27, 2017</p>	
<p>Re.: Press Release</p>	

Dear Sir / Madam,

We enclose herewith a copy of press release dated May 27, 2017, titled Zydus receives final approval from the USFDA for Acamprosate Calcium Delayed-Release Tablets.

The contents of the press release give full details.


Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, Cadila Healthcare Limited



Open H. Shah
Company Secretary



Encl.: As above

Zydus receives final approval from the USFDA for Acamprosate Calcium Delayed-Release Tablets

Ahmedabad, 27 May 2017

Zydus Cadila has received the final approval from the USFDA to market Acamprosate Calcium Delayed-Release Tablets, 333 mg. This medication is used for maintenance of abstinence from alcohol in patients with alcohol dependence.

The drug will be produced at the group's formulations manufacturing facility at Baddi.

The group now has more than 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
